Macrogenics (MGNX) Operating Expenses (2012 - 2026)

Macrogenics (MGNX) has reported Operating Expenses for 15 consecutive years, with $54.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses fell 2.87% year-over-year to $54.2 million; the TTM figure through Mar 2026 stood at $220.7 million (down 12.92% YoY), while the FY2025 annual figure was $222.3 million, down 14.66% from the prior year.
• Operating Expenses improved to $54.2 million in Q1 2026 per MGNX's latest filing, from $53.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $77.7 million in Q1 2022 and bottomed at $45.9 million in Q3 2023.
• Historically, Operating Expenses has averaged $61.0 million across 5 years, with a median of $60.1 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Expenses plunged 31.17% — and 2024, when it increased 23.13%.
• Macrogenics' Operating Expenses stood at $61.1 million in 2022, then retreated by 1.71% to $60.1 million in 2023, then gained by 20.17% to $72.2 million in 2024, then declined by 26.13% to $53.3 million in 2025, then advanced by 1.67% to $54.2 million in 2026.
• Business Quant data shows MGNX's Operating Expenses at $54.2 million in Q1 2026, $53.3 million in Q4 2025, and $54.2 million in Q3 2025.